Marjorie Taylor Greene Criticizes Lack of Support for Cancer Patients Following Bayer’s Supreme Court Roundup Victory
Former Representative Marjorie Taylor Greene has publicly criticized both the U.S. Supreme Court and former President Donald Trump following a significant ruling that favors Bayer AG in a contentious Roundup lawsuit. This ruling, which limited the scope for thousands of state lawsuits claiming that glyphosate, the active ingredient in Roundup, causes cancer, has reignited discussions surrounding the intersection of public health and corporate interests.
In a notable response to the Supreme Court’s 7-2 ruling, which overturned a .25 million jury award stemming from the case of John Durnell—who alleged that prolonged exposure to glyphosate led to his non-Hodgkin lymphoma—Greene expressed her discontent through social media. She lamented that the decision represents a failure to advocate for the rights and health of cancer patients, suggesting that both the Supreme Court and Trump have prioritized corporate protection over public welfare.
The implications of this ruling extend beyond the courtroom. Bayer acquired Roundup through its billion purchase of Monsanto in 2018 and has faced over 100,000 lawsuits alleging that glyphosate is carcinogenic. In response to these legal challenges, Bayer has begun to phase out glyphosate in consumer versions of the herbicide. Greene’s critique becomes particularly resonant as she connects the ruling to broader concerns about accountability and public health.
Justice Brett Kavanaugh, writing for the majority, noted that the Environmental Protection Agency (EPA) has consistently concluded that glyphosate is not a cancer risk, which has influenced the absence of cancer warnings on Roundup labels. Bayer has reiterated its stance, claiming that scientific consensus across various global regulators supports the safety of glyphosate, arguing that much of the litigation relies on outdated assessments.
The controversy surrounding glyphosate has become a political flashpoint, with Greene’s comments reflecting a growing divide over agricultural practices, environmental safety, and corporate influence in government policy. In February, Trump invoked the Defense Production Act to prioritize domestic production of glyphosate-based herbicides, further fanning the flames of this debate.
As the situation unfolds, it underscores the complexities involved in balancing economic interests, consumer safety, and regulatory oversight in the face of ongoing public health discussions.
#business #politics #environment
